CIA
ALNY icon

CSat Investment Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

CSat Investment Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-383
Closed -$56K – 539
2020
Q3 		$56K Buy
383
+32
+9% +$4.55K 0.01% 653
2020
Q2 		$52K Buy
351
+14
+4% +$1.89K 0.01% 672
2020
Q1 		$37K Buy
337
+42
+14% +$4.85K 0.01% 601
2019
Q4 		$34K Buy
295
+53
+22% +$5.28K 0.01% 666
2019
Q3 		$19K Buy
242
+24
+11% +$1.9K 0.01% 716
2019
Q2 		$16K Buy
+218
New +$16.7K 0.01% 730

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

CSat Investment Advisory's ALNY Position: Q4 2020 in Review

CSat Investment Advisory sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 383 shares — an estimated $56K sold.

CSat Investment Advisory first reported a position in ALNY in Q2 2019 and held it in 6 quarters. The position peaked at $56K in Q3 2020. 375 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • CSat Investment Advisory reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 383 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $56K.
  • CSat Investment Advisory first reported a position in Alnylam Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • CSat Investment Advisory's Alnylam Pharmaceuticals position peaked at $56K in Q3 2020.
  • 375 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.